Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Cell Transformation, Neoplastic

sorafenib has been researched along with Cell Transformation, Neoplastic in 26 studies

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (15.38)29.6817
2010's17 (65.38)24.3611
2020's5 (19.23)2.80

Authors

AuthorsStudies
Chen, C; Deng, Q; Li, J; Shao, C; Shi, Z; Sun, H; Tang, W; Xiao, J; Xuan, Z; Ye, S; Yue, J; Zhang, L; Zhao, Y; Zheng, J; Zhu, F1
Chen, J; Jin, Z; Li, H; Xiong, Z; Zhang, B; Zhang, S; Zheng, Y; Zhu, X1
Chen, B; Li, Q; Liu, B; Luo, M; Miao, J; Song, G; Zeng, K1
Han, L; Li, T; Lin, Y; Ma, D; Ma, X; Qin, Z; Qiu, Y; Sun, C; Sun, Y; Zhao, Y; Zhu, L1
Gong, W; Hu, W; Shao, L; Wang, F; Xu, J; Xu, W; Zhou, Y; Zhu, Y1
Chen, C; Chen, SZ; Cheng, Z; Cong, WM; Ding, J; Lee, TKW; Li, XF; Lu, XY; Ning, BF; Qu, L; Shen, WF; Sun, W; Wang, HY; Wen, W; Xia, MY; Xiang, DM; Yang, W; Zhou, TF1
Eriksson, J; Hendrikse, NH; Poot, AJ; Rongen, M; Schuit, RC; Stigter-van Walsum, M; van der Wildt, B; van Dongen, GA; Windhorst, AD1
Amann, J; Araujo, L; Carbone, DP; Greulich, H; Horn, L; Imielinski, M; Kaplan, B; Meyerson, M; Schiller, J; Villalona-Calero, MA1
Haybaeck, J; Petru, E; Smolle, E; Taucher, V1
Chen, C; Daily, MF; Galuppo, R; Gedaly, R; Maynard, E; Shah, M; Spear, BT1
Altomonte, J; Braren, R; Dworniczak, J; Ebert, O; Esposito, I; Feuchtinger, A; Groß, C; Heid, I; Heß, J; Rummeny, E; Sayyed, S; Schlitter, AM; Schwaiger, M; Settles, M; Steiger, K; Steingötter, A; Unger, K; Walch, A; Zitzelsberger, H1
Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T1
Garcia-Manero, G; Hu, Y; Huang, A; Huang, P; Ju, HQ; Li, J; Li, Y; Lu, WH; Sun, Y; Wen, S; Xu, RH; Yang, J; Zhan, G1
Aractingi, S; Arnault, JP; Escudier, B; Grange, JD; Malka, D; Mateus, C; Poirier-Colame, V; Robert, C; Sibaud, V; Soria, JC; Spatz, A; Tomasic, G; Wechsler, J1
DeNicola, GM; Karreth, FA; Tuveson, DA; Winter, SP1
Peter, S; Rohde, D; Tong, TQ1
Couto, JP; Martins, TC; Prazeres, H; Rodrigues, F; Soares, P; Sobrinho-Simões, M; Torres, J; Trovisco, V; Vinagre, J1
Caronia, LM; Phay, JE; Shah, MH1
Fukumoto, M; Ichida, T; Matsuda, Y1
Giménez-Bachs, JM; Nam Cha, S; Salinas-Sánchez, AS; Sánchez-Prieto, R; Serrano-Oviedo, L1
Akli, S; Duong, MT; Hunt, KK; Keyomarsi, K; Liu, W; Lu, Y; Mills, GB; Wei, C; Wingate, HF; Yi, M1
Cagan, RL; Dar, AC; Das, TK; Shokat, KM1
Fuziwara, CS; Hirokawa, M; Matsuse, M; Mitsutake, N; Miyauchi, A; Nishihara, E; Ogi, T; Saenko, VA; Suzuki, K; Tanimura, S; Yamashita, S1
Friedman, SL1
Colombi, M; Kiser, KF; Moroni, C1
Carter, C; Gollob, JA; Kelley, SL; Wilhelm, S1

Reviews

6 review(s) available for sorafenib and Cell Transformation, Neoplastic

ArticleYear
Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
    Anticancer research, 2014, Volume: 34, Issue:4

    Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; Disease Progression; Epithelial-Mesenchymal Transition; Female; Histone Deacetylase Inhibitors; Humans; Molecular Targeted Therapy; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Signal Transduction; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome

2014
Progress in the management of advanced renal cell carcinoma (RCC).
    Aktuelle Urologie, 2010, Volume: 41 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Everolimus; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein

2010
Role of BRAF in thyroid oncogenesis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-15, Volume: 17, Issue:24

    Topics: Benzenesulfonates; Cell Transformation, Neoplastic; Genetic Predisposition to Disease; Humans; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Treatment Outcome

2011
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
    Medical molecular morphology, 2011, Volume: 44, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases

2011
[Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma].
    Actas urologicas espanolas, 2012, Volume: 36, Issue:2

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyridines; Radiation Tolerance; Sorafenib; Von Hippel-Lindau Tumor Suppressor Protein

2012
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Seminars in oncology, 2006, Volume: 33, Issue:4

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Extracellular Signal-Regulated MAP Kinases; Melanoma; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Isoforms; Protein Kinase Inhibitors; Pyridines; raf Kinases; Signal Transduction; Sorafenib

2006

Trials

1 trial(s) available for sorafenib and Cell Transformation, Neoplastic

ArticleYear
In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
    Endocrine-related cancer, 2011, Volume: 18, Issue:4

    Topics: Adult; Aged; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Blotting, Western; Carcinoma, Medullary; Case-Control Studies; Cell Transformation, Neoplastic; Cells, Cultured; Female; Germ-Line Mutation; Humans; Kidney; Luciferases; Male; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutagenesis, Site-Directed; Niacinamide; NIH 3T3 Cells; Pedigree; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Thyroid Neoplasms; Transcription Factor 4; Transcription Factors; Young Adult

2011

Other Studies

19 other study(ies) available for sorafenib and Cell Transformation, Neoplastic

ArticleYear
TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC.
    Cell death & disease, 2022, 05-11, Volume: 13, Issue:5

    Topics: Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Humans; Kidney Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase Kinases; Serine; Sorafenib

2022
ABI2-mediated MEOX2/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence.
    Liver international : official journal of the International Association for the Study of the Liver, 2022, Volume: 42, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Transformation, Neoplastic; Homeodomain Proteins; Humans; Kruppel-Like Factor 4; Liver Neoplasms; Nanog Homeobox Protein; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Sorafenib; Transcription Factors

2022
CPT2-mediated fatty acid oxidation inhibits tumorigenesis and enhances sorafenib sensitivity via the ROS/PPARγ/NF-κB pathway in clear cell renal cell carcinoma.
    Cellular signalling, 2023, Volume: 110

    Topics: Carcinogenesis; Carcinoma; Carcinoma, Renal Cell; Carnitine O-Palmitoyltransferase; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Fatty Acids; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; NF-kappa B; PPAR gamma; Reactive Oxygen Species; Sorafenib

2023
NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway.
    Cell death & disease, 2020, 03-06, Volume: 11, Issue:3

    Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Liver Neoplasms; Mice; Nod2 Signaling Adaptor Protein; Sorafenib

2020
TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction.
    Gene, 2020, Aug-30, Volume: 753

    Topics: Adult; AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; DNA-Binding Proteins; DNA, Mitochondrial; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Middle Aged; Mitochondria; Mitochondrial Proteins; Sorafenib; Transcription Factors; Up-Regulation

2020
Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:6

    Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Cell Self Renewal; Cell Transformation, Neoplastic; Chromosomal Instability; Chronic Disease; Female; Humans; Inflammation; Interleukin-6; Keratin-19; Liver; Liver Neoplasms; Macrophages; Male; Mice; Middle Aged; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Rats, Wistar; Sorafenib; src-Family Kinases; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha

2017
[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
    Nuclear medicine and biology, 2013, Volume: 40, Issue:4

    Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; Cell Transformation, Neoplastic; Male; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Radioactive Tracers; Radiochemistry; Rats; Sorafenib

2013
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
    The Journal of clinical investigation, 2014, Volume: 124, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Amino Acid Substitution; Antineoplastic Agents; Cell Transformation, Neoplastic; DNA, Neoplasm; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation, Missense; Niacinamide; Oncogenes; Phenylurea Compounds; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Sorafenib

2014
Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
    Anticancer research, 2014, Volume: 34, Issue:4

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Synergism; Female; Humans; Immunophenotyping; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; Sulfonamides; Survivin; Wnt Signaling Pathway

2014
Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Oct-01, Volume: 21, Issue:19

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Disease Models, Animal; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Neoplasm Grading; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Sorafenib

2015
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
    Oncotarget, 2016, Jan-26, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Carcinoma, Hepatocellular; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Hepatectomy; Hepatitis; Immunoenzyme Techniques; Inflammation; Liver Neoplasms; Liver Regeneration; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Array Analysis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib

2016
ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
    Leukemia, 2017, Volume: 31, Issue:10

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line; Cell Transformation, Neoplastic; Deoxyglucose; fms-Like Tyrosine Kinase 3; Glycolysis; Hematopoietic Stem Cells; Hexokinase; Humans; Hydrocarbons, Brominated; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Microsatellite Repeats; Mitochondria; Molecular Targeted Therapy; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Propionates; Proto-Oncogene Proteins c-akt; Sorafenib

2017
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Female; Follow-Up Studies; Humans; Keratinocytes; Keratoacanthoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Time Factors

2009
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Molecular cell, 2009, Nov-13, Volume: 36, Issue:3

    Topics: Animals; Benzenesulfonates; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Enzyme Activation; Humans; Immunoprecipitation; MAP Kinase Signaling System; Melanoma; Mice; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; ras Proteins; Sorafenib; Transfection

2009
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
    PLoS genetics, 2012, Volume: 8, Issue:3

    Topics: Acinar Cells; Animals; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin E; Cyclin-Dependent Kinase 2; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Isoforms; Proto-Oncogene Proteins B-raf; Purines; Pyridines; Retrospective Studies; Roscovitine; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases

2012
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
    Nature, 2012, Jun-06, Volume: 486, Issue:7401

    Topics: Animals; Benzenesulfonates; Cell Transformation, Neoplastic; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Extracellular Signal-Regulated MAP Kinases; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Molecular Targeted Therapy; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Polypharmacy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; src-Family Kinases; Survival Rate; Xenograft Model Antitumor Assays

2012
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
    International journal of cancer, 2013, Feb-01, Volume: 132, Issue:3

    Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; COS Cells; DNA, Neoplasm; Humans; Mice; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms

2013
Focus.
    Journal of hepatology, 2012, Volume: 57, Issue:5

    Topics: Animals; Cell Transformation, Neoplastic; Epithelial-Mesenchymal Transition; Hepatic Veno-Occlusive Disease; Hepatitis C; Hepatocytes; Humans; Male; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Monocrotaline; Niacinamide; Phenylurea Compounds; Sorafenib; Viral Nonstructural Proteins

2012
Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants.
    Oncogene, 2006, Oct-26, Volume: 25, Issue:50

    Topics: Aminacrine; Benzenesulfonates; Butadienes; Cell Transformation, Neoplastic; Clone Cells; Frameshift Mutation; Genes, Dominant; Genes, Recessive; Hematopoiesis; Humans; Interleukin-3; MAP Kinase Kinase Kinases; Mutagenesis, Insertional; Neoplastic Stem Cells; Niacinamide; Nitriles; Nitrogen Mustard Compounds; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Retroviridae; Sorafenib; STAT5 Transcription Factor; Transfection

2006